This product has a broad-spectrum antimicrobial effect in vitro, including aerobic Gram-negative and Gram-positive bacteria, anaerobes, Rickettsia, spirochetes and Chlamydia. It has bactericidal effects on the following bacteria: influenza bacillus, Streptococcus pneumoniae and Neisseria meningitidis. It only has antibacterial effects on the following bacteria: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, group B hemolytic Streptococcus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella typhi, Salmonella paratyphi, Shigella, Bacteroides fragilis and other anaerobic bacteria. The following bacteria are usually resistant to chloramphenicol: Pseudomonas aeruginosa, Acinetobacter, Enterobacter, Serratia marcescens, indole-positive Proteus, methicillin-resistant Staphylococcus and Enterococcus. This product is an antibacterial agent. Chloramphenicol is fat-soluble and enters bacterial cells by diffusion, and reversibly binds to the 50S subunit of the bacterial ribosome, which blocks the growth of the peptide chain (possibly due to the inhibition of the action of transpeptidase), thereby inhibiting the formation of peptide chains and preventing protein synthesis.

It is an aminoglycoside antibiotic. It has good antibacterial effects on most Enterobacteriaceae such as Escherichia coli, Klebsiella, Enterobacter, Proteus, Shigella, Salmonella, Citrobacter, Providencia, Yersinia, etc.; influenza bacillus, Brucella, meningococci, gonococci, etc. are also mostly sensitive to this product. Kanamycin also has a certain effect on Staphylococcus (methicillin-sensitive strains) and Mycobacterium tuberculosis, but is ineffective against Pseudomonas aeruginosa. Other Gram-positive bacteria such as hemolytic streptococci, Streptococcus pneumoniae, Enterococcus and anaerobic bacteria are mostly resistant to this product. This product mainly binds to the 30S subunit of the bacterial ribosome and inhibits bacterial protein synthesis. In recent years, the number of resistant strains has increased significantly, because some bacteria produce aminoglycoside inactivating enzymes, which make them lose their antibacterial activity. Kanamycin has complete cross-resistance with streptomycin and neomycin, and may have partial cross-resistance with other aminoglycosides.

This product can inhibit platelet aggregation and prevent thrombosis. It can also counteract vascular damage caused by 5-hydroxytryptamine and bradykinin, increase capillary resistance, reduce capillary permeability, and prevent edema caused by increased vascular permeability.

This product is an intravenous alprostadil preparation with lipid microspheres as drug carriers. Due to the encapsulation of lipid microspheres, alprostadil is not easy to be inactivated. In addition, this product has the targeting characteristics of being easily distributed to damaged blood vessels, thereby exerting the effects of this product in dilating blood vessels and inhibiting platelet aggregation.

It has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacteria; it has antibacterial activity against most bacteria of the Enterobacteriaceae family, penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella, Pseudomonas aeruginosa, etc.; it has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only has moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis; it has good antimicrobial effects against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria; it has poor antibacterial activity against anaerobic bacteria; it is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibits DNA synthesis and replication, and causes bacterial death. At present, clinical drug resistance is on the rise, and there is cross-resistance with other quinolones.